Identification of pharmacological inhibitors of the MEK5/ERK5 pathway

被引：132

作者：

Tatake, Revati J. ^{[1
]}

O'Neill, Margaret M. ^{[1
]}

Kennedy, Charles A. ^{[1
]}

Wayne, Anita L. ^{[1
]}

Jakes, Scott ^{[1
]}

Wu, Di ^{[2
]}

Kugler, Stanley Z., Jr. ^{[2
]}

Kashem, Mohammed A. ^{[2
]}

Kaplita, Paul ^{[3
]}

Snow, Roger J. ^{[2
]}

机构：

[1] Boehringer Ingelheim Pharmaceut Inc, Dept Cardiovasc Dis, Ridgefield, CT 06877 USA

[2] Boehringer Ingelheim Pharmaceut Inc, Dept Med Chem, Ridgefield, CT 06877 USA

[3] Boehringer Ingelheim Pharmaceut Inc, Dept Drug Discovery Support, Ridgefield, CT 06877 USA

来源：

BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS | 2008年 / 377卷 / 01期

关键词：

MEK5; ERK5; Kinase inhibitors; Pharmacological inhibitors;

D O I：

10.1016/j.bbrc.2008.09.087

中图分类号：

Q5 [生物化学]; Q7 [分子生物学];

学科分类号：

071010 ; 081704 ;

摘要：

We have identified two novel MEK5 inhibitors, BIX02188 and BIX02189, which inhibited catalytic function of purified, MEK5 enzyme. The MEK5 inhibitors blocked phosphorylation of ERK5, without affecting phosphorylation of ERK1/2 in sorbitol-stimulated HeLa cells. The compounds also inhibited transcriptional activation of MEF2C, a downstream substrate of the MEK5/ERK5 signaling cascade, in a cellular trans-reporter assay system. These inhibitors offer novel pharmacological tools to better characterize the role of the MEK5/ERK5 pathway in various biological systems. (C) 2008 Elsevier Inc. All rights reserved.

引用

页码：120 / 125

页数：6

共 50 条

[21] A network-based drug prioritization and combination analysis for the MEK5/ERK5 pathway in breast cancer
Odongo, Regan
Demiroglu-Zergeroglu, Asuman
Cakir, Tunahan
BIODATA MINING, 2024, 17 (01)
[22] SPECIFICAL INTERACTIONS BETWEEN NEWLY IDENTIFIED HUMAN KINASES, MEK5 AND ERK5
ZHOU, GC
BAO, A
GUAN, KL
DIXON, JE
FASEB JOURNAL, 1995, 9 (06): : A1306 - A1306
[23] Analysis of aryl substitution and intramolecular ligand H-bonding in selective inhibitors of the MEK5/ERK5 cascade
Flaherty, Patrick T.
Cavanaugh, Jane C.
Gupta, Mohit
Vechery, Colin
Chakrabarty, Suravi
Monlish, Darlene
Wright, Thomas
CANCER RESEARCH, 2015, 75
[24] MEK5/ERK5 signaling: Regulation of smooth muscle A-actin promoter activity
Kaplan-Albuquerque, N
Nemenoff, RA
BIOPHYSICAL JOURNAL, 2001, 80 (01) : 69A - 70A
[25] MEK5/ERK5 Signaling Modulates Endothelial Cell Migration and Focal Contact Turnover
Spiering, Desiree
Schmolke, Mirco
Ohnesorge, Nils
Schmidt, Marc
Goebeler, Matthias
Wegener, Joachim
Wixler, Viktor
Ludwig, Stephan
JOURNAL OF BIOLOGICAL CHEMISTRY, 2009, 284 (37) : 24972 - 24980
[26] MEK5 and ERK5 are mediators of the pro-myogenic actions of IGF-2
Carter, Emma J.
Cosgrove, Ruth A.
Gonzalez, Ivelisse
Eisemann, Joan H.
Lovett, Fiona A.
Cobb, Laura J.
Pell, Jennifer M.
JOURNAL OF CELL SCIENCE, 2009, 122 (17) : 3104 - 3112
[27] Activation of the MEK5/Erk5 MAP kinase signalling pathway elicits a vasoprotective phenotype in primary human endothelial cells
Ohnesorge, N.
Endres, N.
Viemann, D.
Spiering, D.
Roth, J.
Ludwig, S.
Goebeler, M.
Schmidt, M.
EXPERIMENTAL DERMATOLOGY, 2009, 18 (03) : 322 - 322
[28] MEK5/ERK5 activation regulates colon cancer stem-like cell properties
Diane M. Pereira
Sofia. E. Gomes
Pedro M. Borralho
Cecília M. P. Rodrigues
Cell Death Discovery, 5
[29] Effects of MEK5/ERK5 association on small ubiquitin-related modification of ERK5: Implications for diabetic ventricular dysfunction after myocardial infarction
Shishido, Tetsuro
Woo, Chang-Hoon
Ding, Bo
McClain, Carolyn
Molina, Carlos A.
Yan, Chen
Yang, Jay
Abe, Jun-ichi
CIRCULATION RESEARCH, 2008, 102 (11) : 1416 - 1425
[30] MEK5/ERK5 activation regulates colon cancer stem-like cell properties
Pereira, Diane M.
Gomes, Sofia E.
Borralho, Pedro M.
Rodrigues, Cecilia M. P.
CELL DEATH DISCOVERY, 2019, 5 (1)

← 1 2 3 4 5 →